Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

  03 January 2020

Antabio SAS, the biopharmaceutical company focused on developing a
broad pipeline of antibacterial treatments against life threatening WHO critical priority pathogens, announces that it has been awarded up to $4.4 million in a second tranche funding from CARB-X, the global nonprofit partnership dedicated to tackling the global rising threat of drug-resistant bacteria. The funding is to support the development of Antabio’s novel small molecule candidate for the treatment of Pseudomonas
aeruginosa infections in Cystic Fibrosis (CF) patients.

Further reading: Antabio
Author(s): Antabio
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!